Adagene Inc (STU:978)
€ 2.52 -0.14 (-5.26%) Market Cap: 111.56 Mil Enterprise Value: 41.72 Mil PE Ratio: 0 PB Ratio: 2.07 GF Score: 32/100

Adagene Inc at Jefferies China Biotech Summit (Virtual) Transcript

Oct 26, 2021 / 07:00PM GMT
Release Date Price: €10.1 (+2.02%)
Dingding Shi
Jefferies LLC, Research Division - Equity Analyst

Thank you for joining Jefferies China Biotech Summit. And for this company presentation, we have Adagene, and we are very pleased to have Chief Executive Officer, Dr. Peter Luo, for this session. Peter, welcome, and pass it to you.

Peter P. Luo
Adagene Inc. - Co-Founder, CEO & Chairman of the Board

Thank you, Kelly, and thanks, everyone. And today, I'd like to give a company overview and with the latest update as a disclaimer. And I'd like to always emphasize our goal at Adagene here, is really use computational power to drive the directed evolution process. And so by leveraging our AI-powered Dynamic Precision Library approach, we'd like to bring highly differentiated antibody-based drugs to cancer patients worldwide.

I think at Adagene, we are really leveraging this platform to make things very differently with a lot of differentiation. And we really believe life is a motion and so are proteins and the antibody we are working with. So in this way, we'll be able to engage the target

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot